Liposomes versus metallic nanostructures: differences in the process of
  knowledge translation in cancer by Fajardo-Ortiz, David et al.
© 2014 Fajardo-Ortiz et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
International Journal of Nanomedicine 2014:9 2627–2634
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2627
O r I g I N a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/IJN.S62315
Journal name: International Journal of Nanomedicine
Journal Designation: Original Research
Year: 2014
Volume: 9
Running head verso: Fajardo-Ortiz et al
Running head recto: Nanostructures: knowledge translation in cancer
DOI: http://dx.doi.org/10.2147/IJN.S62315
David Fajardo-Ortiz1
luis Duran1
laura Moreno1
héctor Ochoa2 
Víctor M castaño1,3,4
1Faculty of Medicine of the National 
autonomous University of Mexico, 
Mexico city, Mexico; 2el colegio 
de la Frontera sur, san cristobal 
de las casas, Mexico; 3Molecular 
Material Department, applied Physics 
and advanced Technology center, 
National autonomous University of 
Mexico, Juriquilla, Mexico; 4advanced 
Technology center, cIaTeQ, 
Queretaro, Mexico
correspondence: Víctor M castaño 
centro de Física aplicada y Tecnología 
avanzada, Universidad Nacional 
autónoma de México, Boulevard Juriquilla 
3001, Juriquilla, Queretaro 76230, México
Tel +1 442 211 2657
Fax +1 442 192 6129
email meneses@unam.mx
liposomes versus metallic nanostructures: 
differences in the process of knowledge 
translation in cancer
Abstract: This research maps the knowledge translation process for two different types of 
nanotechnologies applied to cancer: liposomes and metallic nanostructures (MNs). We performed 
a structural analysis of citation networks and text mining supported in controlled vocabularies. 
In the case of liposomes, our results identify subnetworks (invisible colleges) associated with 
different therapeutic strategies: nanopharmacology, hyperthermia, and gene therapy. Only in 
the pharmacological strategy was an organized knowledge translation process identified, which, 
however, is monopolized by the liposomal doxorubicins. In the case of MNs, subnetworks are 
not differentiated by the type of therapeutic strategy, and the content of the documents is still 
basic research. Research on MNs is highly focused on developing a combination of molecular 
imaging and photothermal therapy.
Keywords: nanotechnology, citation network analysis, basic research, clinics, health care
Introduction
Cancer is a growing global health problem: it is estimated that the incidence of new 
cases of cancer will double by 2030 compared to 2008.1 Population aging is the main 
force that drives the increased incidence of cancer.2 It has been suggested that the 
potential adverse effects associated with demographic and epidemiological changes that 
will occur in the coming decades could be mitigated by technological development.3 
However, the technological innovation process is not guided by the burden of disease 
except in the case of cancers and cardiovascular diseases, and even when these disease 
groups are disaggregated, correlation is lost.4 Moreover, nanotechnology has been 
mentioned as a promising source of alternative treatments and diagnostic methods for 
cancer.5,6 However, until now, there has been no clear evidence that the evolution of 
knowledge about cancer nanotechnology will lead to innovations in the fight against 
cancer. On the other hand, it is not well understood how the disruptive character of 
cancer nanotechnology7 could affect its translation into clinical applications.
A technology is disruptive because it breaks with the “normal” line of techno-
logical development of a particular class of products.8 Disruptive technologies allow 
the entry of new competitors in a given market, which implies a potential threat to 
incumbents.9 The opposition between dominant and disruptive technologies is relative: 
there is a technology development cycle in which dominant designs were originally 
disruptive innovations.10 In this study, we propose that nanotechnologies are not a 
homogeneous group and that they are in different stages of evolution of technologi-
cal development.
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In this study, we compared the knowledge translation 
for two different kinds of nanotechnologies – liposomes 
and metallic nanostructures – which, because of their tem-
porality, are clearly in two different stages of technologi-
cal development. The former is still in a preclinical stage, 
whereas the latter is already a reality in the pharmaceuti-
cal market. Our objective is mainly methodological and 
exploratory: we are developing a way to map the knowledge 
translation through scientific literature networks in health 
nanotechnologies; along that line, we are using these two 
very different types of nanotechnologies as case studies, 
since this allows us to obtain a contrasting view of how 
different the structure, organization, and translation of 
knowledge look in regard to a consolidated technology, 
such as liposomes, and for a very new therapeutic tool, 
such as metallic nanostructures. 
Liposomes are “phospholipid bubbles with a membrane 
bilayer structure”,11 which, because of their size, are located on 
the border between micro- and nanotechnology.12 Liposomes 
were among the first nanotechnologies to be used in clinical 
trials and among the first to appear on the market.13 Regarding 
their applicability, Sen and Mandal point out that:
Efficient entrapment of therapeutics, biocompatibility, bio-
degradability, low systemic toxicity, low immunogenicity 
and ability to bypass multidrug resistance mechanisms has 
made liposomes a versatile drug/gene delivery system in 
cancer chemotherapy.14 
Liposomes are the dominant design among nanotechnolo-
gies applied to cancer treatment.
The biomedical use of metallic nanostructures, mainly 
gold, has been identified as a new paradigm of cancer 
treatment and diagnosis.15,16 Gold nanostructures have the 
advantage of being nontoxic, inert, easy to synthesize, and 
versatile.17 However, the most revolutionary qualities of 
metallic nanostructures in the development of cancer treat-
ments are their optical properties. Surface plasmon resonance 
of metallic nanostructures increases the absorption and 
scattering of light, which has application in cancer imaging, 
spectroscopic detection, and photothermal therapy.18,19 The 
metal nanostructures are a radical innovation compared with 
liposomes.
As mentioned above, the current study seeks to com-
pare knowledge translation in these two nanotechnologies 
applied to cancer. The knowledge translation has been 
studied in citation networks through two methodologi-
cal strategies. The first strategy is to classify documents 
into two areas of research: the first area is focused on the 
“discovery”, while the second is focused on the “delivery”. 
Subsequently, network analysis is performed to identify the 
“main paths” in each field, and, finally, to identify citations 
that connect them.20,21 The second strategy is to classify 
journals into four categories ranging from basic research 
to clinical observation, according to the terms used in the 
titles of the articles, and then map the citations among the 
journals.22,23 
An alternative methodological approach to the two men-
tioned above was developed by us to study the translation 
of knowledge on cervical cancer.24 This strategy is based on 
the modeling of networks of highly cited papers, which are 
semantically analyzed using controlled vocabularies of the 
Medical Subject Headings (MeSH)25 and the Gene Ontology 
(GO).26 This strategy, by and large, was the one used in this 
investigation.
Methods
The following steps were undertaken in this study:
1. A search for articles (November 2013) on cancer and 
liposomes, or cancer and metallic nanostructures, was 
performed in the Web of Science (WOS).27 The search 
criteria are shown in Table 1. 
2. The 20% most cited articles, which together accounted 
for at least 60% of the citations in their respective fields, 
were selected and downloaded from WOS.
3. Cytoscape version 2.8.1 (The Cytoscape Consortium, 
San Diego, CA, USA),28 HistCite29 (Eugene Garfield, 
Thomson Reuters Corporation), and  Pajek version 3.1430 
(Vladimir Batagelj and Andrej Mrvar, University of 
Ljubljana)  software were used to construct two network 
models. The first network model corresponds to cancer 
research and liposomes, while the second comprises 
documents on cancer and metallic nanoparticles.
4. The scientific papers that constitute the body of network 
models were sought on the GoPubMed31 website (http://
www.gopubmed.org/web/gopubmed/), which semanti-
cally analyzes and labels the documents with GO and 
MeSH terms.
5. The Clust & See32 application (Laboratoire TAGC/
INSERM U1090, Marseille, France) was used to identify 
subnetworks (subnets) within the models. Identification 
of subnets and distribution of MeSH terms was conducted 
to identify research areas within each field.
6. MeSH terms that are embedded within the higher hier-
archy categories “Diagnosis”, “Therapeutics”, “Surgical 
Procedures, Operative”, “Named Groups”, and “Health 
Care” are considered clinical terms. The terms that are 
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outside of these categories, and GO terms are considered 
nonclinical terms.
7. The proportion of clinical versus nonclinical terms was 
calculated for each document in the network model. This 
ratio is a measure of how clinical or basic a paper is.
8. Each document that is part of the network model was 
tagged with information about the institution, city, and 
country of origin.
Results 
liposomes
Following the criteria outlined in Table 1, 1,456 papers on 
cancer and liposomes were found. Of these, 291 (20%) were 
selected. These were cited 22,949 times, representing 68.2% 
of all citations (33,657) found in the WOS. The proportion 
of citations shows the importance of these documents in the 
process of scientific communication.
One hundred and fifty-two of the selected articles form 
a single network of citations. By analyzing the network 
model using the Clust & See software, nine subnets were 
identified (Figure 1). The distribution of GO and MeSH 
terms identified for each subnet reveals that several of these 
correspond to different lines of research (Figure 1). Subnet 1 
is related to the development of liposomes as vehicles for 
drugs in general; subnet 2 is related to the clinical use of 
liposome-encapsulated doxorubicin; subnet 3 is related to 
basic research into doxorubicin liposomes; subnet 4 relates 
to clinical research of gene therapy; subnet 5 also relates to 
gene therapy but at the level of basic research; subnet 7 is 
associated with hyperthermia therapy; and subnet 9 is related 
to small RNA interference.  
Research on liposomes and cancer is basic except in 
subnet 2 (Figure 1), which is composed mainly of Phase II 
and Phase III clinical trials and multicenter randomized trials. 
Research on liposomes and cancer is largely dominated by 
the United States, followed by Europe, Canada, Japan, and 
Taiwan (Figure 1). The University of Texas MD Anderson 
Cancer Center, Houston, TX, USA stands out as the leading 
institution, with 15 papers included in the network model 
(Table 2). 
Metallic nanostructures
Six hundred and seventy-seven articles on metal nanostruc-
tures and cancer were found, of which 137 (20%) were 
selected, which were cited 12,878 times, representing 76.3% 
(16,884) of all citations made to the documents. 
Eighty-four of the selected nodes form a single network 
of citations. By analyzing the network model using the 
Clust & See software, six subnets were identified (Figure 2). 
However, the distribution of GO and MeSH terms for each 
subnet shows no differences between subnets in terms of 
clinical or biomedical content, although differences in the 
combination of technology do exist. Subnet 1 is character-
ized by the combined use of metal nanoparticles with carbon 
nanotubes, while, in subnet 2, the research is characterized by 
combining laser and nanoparticles. Finally, subnet 6 relates to 
phototherapy. Subnets 3, 4, and 5 are associated with terms 
that are common to all documents in the network model. 
Generally, the items that make up the network model are 
basic research, with some scattered clinical research articles 
in subnets 1 and 2 (Figure 2).
Research in cancer and metallic nanostructures is strongly 
dominated by the United States, followed by China and South 
Korea. The institution leadership is split between the Rice 
University in Houston, TX, USA and the Georgia Institute 
of Technology in Atlanta, GA, USA, with seven documents 
for each institution within the network model.
Discussion
Liposomes and metallic nanostructures differ in their 
network structure, knowledge translation, and leadership 
by country and institution. How relevant are these differ-
ences and how are they related to the concepts of disruptive 
technologies and dominant designs? What can these maps 
tell us about the forces that guide the development of these 
nanotechnologies?
Table 1 search criteria of the articles in the Web of science
Nanotechnology Title Topic Document type Timespan
liposomes cancer* or carcinoma* liposome* article all years
Metallic 
nanostructures
cancer* or carcinoma* “gold nanoparticle*” or “au nanoparticle*” or “metal 
nanoparticle*” or “silver nanoparticle*” or “ag nanoparticle*” 
or “gold nanorod*” or “au nanorod*” or “metal nanorod*”  
or “silver nanorod*” or “ag nanorod*” or “gold nanoshell*” or 
“au nanoshell*” or “metal nanoshell*” or “silver nanoshell*” or 
“ag nanoshell*”
article all years
Note: *wild card.
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Figure 1 Network model of research papers on cancer and liposomes.
Notes: each node represents one paper of the 20% most cited papers on liposome research applied to cancer, and the edges represent the citations between the documents 
(nodes). The shape of the nodes indicates to which subnetwork they belong (1–9). The color of the nodes is according to a continuous scale from red to blue. This scale is 
a function of the clinical terms rate, so a red node could be considered a basic research paper, a purple one clinical research, and a blue node is a clinical observation article. 
Nodes without text are papers that did not report any address.
Let us begin by briefly discussing the scope of the results. 
The maps (Figures 1 and 3) show that the most cited papers 
cite each other. High citation is not necessarily related to 
the quality or validity of a research paper;33,34 however, the 
most cited papers, which in turn cited each other, represent 
the paradigmatic core of a given area of knowledge.35 If the 
contents of these documents reflect the essential components 
of a particular paradigm, analyzing the content is relevant 
since paradigms dictate the guidelines on how to understand 
and treat a health problem.36
liposomes
The network model shows how research on liposomes and 
cancer is dominated by a pharmaceutical approach over other 
potential therapeutic strategies such as hyperthermia and gene 
therapy. This pharmaceutical approach is in turn dominated 
by the use of liposomes as carriers of doxorubicin. The 
results also show a translation of basic research into clinical 
knowledge through the interaction between the two subnets 
associated with doxorubicin (subnets 2 and 3; see Figure 1), 
which is related to the fact that Doxil® (Janssen Products, LP, 
Horsham, PA, USA) was the first nanodrug approved by the 
US Food and Drug Administration (FDA) in 1995.37 
Our research was not focused on the line of innovation 
and development of Doxil, even though this may be in 
relative terms the dominant design of liposomes applied to 
cancer, because our search form focused on identifying the 
“paradigmatic body” of the liposomes and cancer research, 
with emphasis on documents whose headings include the 
words “cancer” or “carcinoma”. However, FDA approval 
of Doxil was a milestone that likely radically affected the 
evolution of knowledge on liposomes and cancer. Twenty-six 
of the 28 documents that belong to subnet 3, which relates to 
clinical research on liposomes, are subsequent to 1995, and 
12 of them are about Doxil. These documents dominate the 
communication process in subnet 3 (Figure 3).
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The oldest and most central document in subnet 3 is about 
Doxil (Figure 3) is a Phase II clinical trial aimed at treating 
advanced breast cancer.38 Given that Doxil was originally 
approved for the treatment of Kaposi’s sarcoma,37 we con-
jecture that subnet 3 corresponds to the phase of imitation of 
Doxil previously reported by Venditto and Szoka,39 whose 
document is based on a model of inventors, innovators, 
and imitators inspired by the ideas of Schumpeter.40 The 
invention phase is made up of scientific and technological 
developments prior to the innovation stage, which begin with 
the optimization of remote loading of the drug in  liposomes, 
continue with clinical trials, and end with approval by the 
FDA,39 while the imitation phase seeks to improve the 
product or extend its use to solve other problems. As such, 
subnet 3 would focus on extending and/or improving the 
clinical use of Doxil. This makes sense if we consider that 
this methodology identifies the paradigmatic body of normal 
science in Kuhnian terms, not in revolutionary science that 
is equivalent to a phase of technological innovation. 
One question arose constantly throughout this investiga-
tion: why is there such a marked hierarchy, in which Doxil 
dominates over other liposomal doxorubicin formulations 
Table 2 leading institutions in liposome and cancer research
Institution Location Number of papers
The University of Texas MD anderson cancer center houston, TX, Usa 15
University of alberta edmonton, aB, canada 8
Nagoya University Nagoya, Japan 7
roswell Park cancer Institute Buffalo, NY, Usa 6
University of california, san Francisco san Francisco, ca, Usa 6
Figure 2 Network model of research papers on cancer and metallic nanostructures.
Notes: each node represents one paper of the 20% most cited papers on liposome research applied to cancer, and the edges represent the citations between the documents 
(nodes). The shape of the nodes indicates to which subnetwork they belong. The color of the nodes is according to a continuous scale from red to blue. This scale is a function 
of the clinical terms rate, so a red node could be considered a basic research paper, a purple one clinical research, and a blue node is a clinical observation article. subnet 1 
is related to nanotubes, subnet 2 is related to lasers and subnet 6 is related to phototherapy; the other networks (3–5) are not displayed because they are generals.
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 technology and market. We could reinterpret the above 
as a complex process of negotiation between different 
fields of knowledge and actors, and between market 
and technology, all of which are deeply related to the 
concept of trading zones.42 The emergence of these areas 
requires, inter alia, the construction of a new creole lan-
guage.43 This requires dialogue and negotiation between 
fields of knowledge and actors which carry with them 
a set of prior epistemic commitments, several of which 
must be broken.
2. Barenholz, one of the inventors of Doxil, describes the 
technical difficulty of developing this nanodrug due 
to a combination of physicochemical constraints. For 
example, the liposomes need to be nanosized in order to 
be favored by the effect of enhanced permeability and 
retention, but decreased size affects drug loading into 
liposomes.37 In the same paper, Barenholz notes the dif-
ficulty for imitators to develop a generic version of Doxil 
that succeeds in being approved by the FDA,37 which 
highlights the weight that the combination of regulatory 
and technical barriers could have when trying to innovate 
with nanodrugs.
3. A third argument is related to the difference in time of 
approval between conventional drugs and nanomedicines. 
Of this, Venditto and Szoka said: 
This is probably due to the fact that for most currently 
approved drugs, reformulating them in a nanocarrier pro-
vides a small increase in performance that large pharma-
ceutical companies do not consider being worth the time, 
effort and expense of development.39
As pointed out in the second paragraph of the discussion, 
our results are focused on the paradigmatic literature, leaving 
out the most recent inventions within the field of liposomes 
applied to cancer. One of these promising recent inventions 
is the folate-targeted liposomal (FTL) zoledronic acid (ZOL). 
It has been reported that dipalmitoyl phosphatidylglycerol-
FTL-ZOL showed better in vitro results than PEGylated 
FTL-ZOL, non-folate targeted liposomal ZOL, free ZOL, 
and doxorubicin;44 however results in in vivo preclinical 
research indicate that liposomal ZOL was severely toxic 
for the animals (mice).45 Another research group reported 
positive therapeutic results in a mouse xenograft model with 
increased survival, antitumor activity, and tolerability,46 with 
better results obtained using PEGylated calcium/phosphate 
nanoparticles as ZOL carriers.47 A future study comparing 
the structure and knowledge translation between different 
drug nanocarriers could be relevant. 
Figure 3 subnetwork 2 hierarchically organized.
Notes: each node represents one paper of the 20% most cited papers on liposome 
research applied to cancer, and the edges represent the citations between the 
documents (nodes). The color of the nodes is according to a continuous scale from 
red to blue. This scale is a function of the clinical terms rate, so a red node could be 
considered a basic research paper, a purple one clinical research, and a blue node is 
a clinical observation article.
Abbreviation: PDl, pegylated liposomal doxorubicin.
and the latter dominate the pharmaceutical approach, which 
in turn dominates research on liposomes applied to cancer 
treatment? In other words: why is there so little diversity of 
anticancer products using liposomes?
Three clues can lead us to a partial answer to this 
question:
1. Maine et al41 identify three strategies that led to the 
invention of Doxil: 1) importation of ideas from a 
variety of fields of knowledge, 2) the creation of an 
atmosphere of deep collaboration, and 3) the fit between 
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Metallic nanostructures
Our results indicate that the subnets are not distinguished by 
the therapeutic approach or way of understanding cancer, 
which makes sense given the disruptive, novel (the docu-
ments that make up the network were published between 
2004 and 2012), and basic character of the documents in 
the network. The content of these documents involves a first 
interdisciplinary dialogue between the biomedical sciences 
and metallic nanostructures. The central documents of sub-
nets 1 and 2 illustrate the general strategy of this particular 
type of nanotechnology, which involves taking advantage of 
the increased absorption and scattering of light, and the rapid 
conversion of light into heat energy that occurs in metallic 
nanostructures in order to develop molecular-scale imaging 
and photothermal therapy.48,49 This strategy represents a 
technological breakthrough when compared with liposomes, 
the liposomes found a niche in the pharmaceutical and bio-
technology industry. Metal nanostructures have not yet left 
the universities and research centers; as such, it is difficult 
to define a path that tells us how this nanotechnology will 
reach the patient. The differences in the leading institutions 
and countries where these two different kinds of nanotech-
nologies are developed further emphasize the disruptive 
nature of the metal nanostructures. Institutional leadership 
in the case of liposomes lies with institutions that are global 
leaders in terms of research and treatment of cancer, while, 
for the case of metallic nanostructures, leadership lies in 
the institutions that are already leaders in nanotechnology. 
Asia replaced Western Europe as the United States’ partner 
in the development of metallic nanostructures applied to 
cancer. The last statement is consistent with observations 
that suggest that China is fast becoming a leading nation 
in nanotechnology on par with the United States,50 and that 
nanotechnology can change the landscape of research and 
development on a global scale, allowing the emergence of 
new technological powers.51 
Conclusion
This research is the first attempt to map and compare the 
structure and translation of knowledge about specific types of 
nanotechnologies applied to cancer. Liposomes are a disrup-
tive technology that is in the process of becoming a dominant 
design, exhibiting a process of knowledge translation and 
branches that correspond to different therapeutic strategies. 
However, there is a marked dominance of the pharmaceutical 
approach, which is organized around liposomal doxorubicin. 
While liposomes are moving from a stage of innovation 
to imitation, metallic nanostructures are still in a phase of 
invention, in a first interdisciplinary dialogue between the 
biomedical sciences and nanotechnology, which revolves 
around the development of  photothermal therapy and 
molecular imaging. Finally, the translation of this research 
strategy into a useful tool for decision makers is currently 
under way and will reported separately. 
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